China has witnessed a bullish growth in biotech, with a plethora of labs and biopharmas churning out innovative healthcare solutions. In 2020, Chinese healthcare startups raised $29.3 billion, almost double the 2019 funds. What factors spur the growth of biotech in China? How can companies map a strategy for tapping into the country’s growth and innovation in biotech? How will China’s biotech reshape the global biopharma landscape? What are the opportunities and continuing challenges? And how does US-China tension influence affect the outlook for collaboration?
Join Xiaoqing Boynton, senior director, International Affairs, Biotechnology Innovation Organization; Nisa Leung, Managing Partner, Qiming Venture Partners; Scott Moore, director, Penn Global China Program; and Greg Scott, founder and CEO, ChinaBio Group for the answers!
Nisa Leung is a Managing Partner of Qiming Venture Partners and leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages over USD 5.9 billion in assets and investment in over 380 companies. Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed and U-Systems. Leung was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital. She currently sits on the board of Zai Lab, Venus MedTech, dMed, CanSino Biologics, Chain Medical Labs, New Horizon Health, Berry Oncology, Broncus, Valgen, Insilico Medicine among others. Leung has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020 and 2021, named Best Women VCs List by Forbes China (#2 in 2021, #3 in 2018) and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. Leung earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council, Hong Kong Exchanges and Clearing Limited Board of Directors and Hong Kong Palace Museum.
Scott Moore is a researcher and policymaker focused on emerging environmental and technological challenges. Dr. Moore is currently director of the Penn Global China Program in the Office of the Provost at the University of Pennsylvania, where he works with faculty across the university to design and conduct research on emerging challenges facing China and the world, including climate change, artificial intelligence, and gene editing. Previously, Dr. Moore worked at the World Bank and served as Environment, Science, Technology, and Health Officer for China at the U.S. Department of State through a Council on Foreign Relations International Affairs Fellowship. In that capacity, he was responsible for developing and coordinating all aspects of U.S.-China environmental cooperation, and worked extensively on the Paris Agreement on climate change as well as ocean conservation and civil space cooperation. Before joining State, he was Giorgio Ruffolo Postdoctoral Research Fellow at the Belfer Center for Science and International Affairs at Harvard University. His first book, Subnational Hydropolitics: Conflict, Cooperation, and Institution-Building in Shared River Basins (Oxford University Press, 2018), examines how climate change and other pressures affect the likelihood of conflict over water within countries. His next book, also from Oxford, will examine China’s role in providing public goods and regulating emerging technologies. Dr. Moore holds master’s and doctoral degrees from Oxford University and an undergraduate degree from Princeton.
Greg Scott founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on cross-border investment and partnering, including the ChinaBio® Partnering Forum which draws over 1500 attendees from around the world to China each spring. Scott is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today, a widely read newsletter covering the China life science industry. He also is the current chair for the American Chamber of Commerce Healthcare Committee, and a former board member of BayHelix Group. Scott is considered a leading expert on China’s life science industry and is frequently quoted in media including the Wall Street Journal, Financial Times, Bloomberg, BioWorld, BioCentury, and other industry publications. Headquartered in Shanghai, ChinaBio® has team members in San Diego, Palo Alto, Singapore and Basel, Switzerland.
Xiaoqing Boynton is a Senior Director for International Affairs at the Biotechnology Innovation Organization (BIO), the world’s largest biotech association headquartered in Washington, DC. Drawing on over 15 years of experience in US-China relations and global government affairs, she is responsible for developing and executing BIO’s advocacy strategy with respect to key Asian markets, with a focus on China and Japan. As BIO’s primary lead on Asian policy issues, she works closely with member companies (multinational companies and small and mid-size biotech) and BIO board to support the development of next-generation biotech solutions and create an ecosystem for innovation. Boynton most recently served as a Senior Vice President at Albright Stonebridge Group, a global strategic advisory and commercial diplomacy firm chaired by former Secretary of State Madeleine Albright. Previously, she served as a Fellow at the Center for Strategic and International Studies (CSIS), where she conducted research on China’s socioeconomic transformation and health security issues for its Global Health Policy Center and the Freeman Chair in China Studies. Boynton holds an M.A. in International Development from Brandeis University and a B.A. in International Economics and Trade from Beijing International Studies University.